Nomenclature of HBV core protein-targeting antivirals

Fabien Zoulim*, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William Delaney, Su Wang, Gabriel Westman, Veronica Miller, Harry L.A. Janssen

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

1 Citation (Web of Science)

Abstract

Hepatitis B virus (HBV) core protein-targeting compounds are in or entering clinical development without a standardized nomenclature. We propose a naming convention for these core-targeting antiviral products to provide clarity and accelerate HBV drug development.
Original languageEnglish
Pages (from-to)748-750
Number of pages3
JournalNature Reviews Gastroenterology and Hepatology
Volume19
Issue number12
Early online date7 Oct 2022
DOIs
Publication statusPublished - Dec 2022

Bibliographical note

Funding Information:
F.Z. has received grants from Assembly Biosciences, Beam, Janssen and Viravaxx and is also a consultant for Assembly, Aligos, Antios, Arbutus, Gilead Sciences, GlaxoSmithKline, Janssen and Vir Biotechnology. A.Z. has equity in Assembly Biosciences and serves on their scientific advisory board. A.Z. is also a founder and Chief Scientific Officer of Door Pharmaceutical. J.F. is an employee of Aligos Therapeutics. A.G. is a former employee and current stakeholder of Gilead Sciences. J.H. has been supported by funding from the National Institute of Allergy and Infectious Disease/NIH and Gilead for work relevant here and has consulted for Arbutus, Bristol Myers Squibb, Gilead, Janssen, Roche and Sanofi. O.L. is an employee of Janssen and is a shareholder of Johnson & Johnson. N.M. is an employee of Arbutus Biopharma. W.D. is an employee at Assembly Biosciences and owns stock in Assembly Biosciences and Gilead. S.W. has received funding from Gilead. V.M. receives grant funding for the HBV Forum from Abbott, Aligos Therapeutis, Altimmune, Antios Therapeutics, Assembly Biosciences, Enanta Pharma, Enyo Pharma, Gilead, GlaxoSmithKline, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology and Virion. H.L.A.J. has received grants from AbbVie, Gilead, GlaxoSmithKline, Janssen, Roche and Vir Biotechnology, and is also a consultant for Aligos, Antios, Arbutus, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, VBI Vaccines, Vir Biotechnology and Viroclinics. S.B., E.D., M.K., K.L., M.N. and G.W. declare no competing interests.

Fingerprint

Dive into the research topics of 'Nomenclature of HBV core protein-targeting antivirals'. Together they form a unique fingerprint.

Cite this